Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop
The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.
You may also be interested in...
Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?
The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.
Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.